AVI BioPharma to Present Company Overview at the UBS Global Life Sciences Conference

AVI BioPharma to Present Company Overview at the UBS Global Life Sciences Conference

ID: 65795

Webcast Accessible via AVI Website


(firmenpresse) - BOTHELL, WA -- (Marketwire) -- 09/14/11 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the Company is scheduled to present at the UBS Global Life Sciences Conference in New York, NY, on Wednesday, September 21, at 3:00 p.m. Eastern Time. Chris Garabedian, AVI's President and CEO, will provide a company overview.

The presentation will be webcast live under the events section of AVI's website at and will be archived there following the presentation for 90 days. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.



AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging its highly differentiated RNA-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including eteplirsen, which is in clinical development for the treatment of Duchenne muscular dystrophy, and multiple drug candidates that are in clinical development for the treatment of infectious disease. For more information, please visit .



AVI Media and Investor Contact:
Erin Cox
Manager, Corporate Communications and Investor Relations
425.354.5140


AVI Media Contact:
David Schull
Russo Partners
212.845.4271



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Horizon Pharma to Present at the JMP Securities Healthcare Conference Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 14.09.2011 - 12:00 Uhr
Sprache: Deutsch
News-ID 65795
Anzahl Zeichen: 0

contact information:
Town:

BOTHELL, WA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 240 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"AVI BioPharma to Present Company Overview at the UBS Global Life Sciences Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

AVI BioPharma, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von AVI BioPharma, Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z